A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects

Zhengzhi Liu, Haimiao Yang, Wei Yang et al.|Expert Opinion on Drug Metabolism & Toxicology|2022

Cited by 0